FUKUOKA, Japan--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) (Frankfurt: XMPA) was informed of the completion of enrollment of the 11 patient investigator-initiated RESTORE study in Japan using adipose-derived stem cells to treat the complications of surgery and radiation damage following partial mastectomy for the treatment of breast cancer. The administered cells were extracted and concentrated from the patients’ own adipose tissue using Cytori’s stem cell processing system.
